Seminarios Vall d'Hebron: Avances en Enfermedades Lisosomales

 
  Hotel Alimara, C/Berruguete 126 - Barcelona 08035 —
03/05/2019
03/05/2019 -- From 09:00h to 18:00h
Organize :
Unidad de Enfermedades Metabólicas HereditariasUnidad de Enfermedades Minoritarias
Modality: In-person
Share it:

9:00-9:15 – Opening

9:15-10.45– New treatments for old diseases
Chair: Dra. Mar O’Callaghan, Hospital Sant Joan de Déu, Barcelona 

Dra. Mireia del Toro, Hospital Vall d’Hebron, Barcelona "Lipofuscinosis: importance of early diagnosis and treatment"

Dr. Jesús Villarrubia, Hospital Ramón y Cajal, Madrid "Niemann-Pick type B: new therapeutic opportunities"

Dr. Antonio González Meneses, Hospital Virgen del Rocío, Sevilla "Update in diagnosis and treatment of the mucopolysaccharidosis"
 
10.45-11:15 – Coffee break
 
11:15-12.45 – New diagnostic approaches and research therapeutic strategies 
Chair: Dr. José Antonio Arranz, Hospital Vall d’Hebron, Barcelona

Dr. Cristóbal Colón, Hospital Universitario, Santiago de Compostela "Present situation of the newborn screening for lysosomal diseases"

Dra. Ibane Abasolo, CIBBIM-Nanomedicina, Institut Recerca Vall d’Hebron, Barcelona "Therapeutic applications of extracellular vesicles as vehicles for lysosomal enzymes"

Dr. Víctor Álvarez, Hospital Universitario, Santiago de Compostela  "Vehículos no virales: nueva aplicación para MPS IV"                             

Dra. Silvia Muro, University of Maryland (USA), ICREA - Institut de Bioingenieria de Catalunya, Barcelona "New means to enable blood-to-brain access of lysosomal enzyme therapies"
  
13:00 – 14:00 Buffet/Lunch
  
14:00-16:30 – Treatment and long-term evolution of Gaucher and Fabry diseases
Chairs: Dr. Xavier Solanich, Hospital Bellvitge, and Dr. VicençTorregrosa, Hospital Clínic

Dr. Derralynn Hughes, Royal Free Hospital, UCL, London (UK) "Bone disease and malignancy in Gaucherdisease"

Dr. Gregory Pastores, University College Dublin , Ireland "Guidelines and therapeutic goals in Gaucherdisease"

Dr. Roser Torra, FundacióPuigvert, Barcelona "Early detection and long-term evolution of Fabrynephropathy" 

Dr. Guillem Pintos, Hospital UniversitariValld’Hebron, Barcelona 2Clinical phenotype and genotype in the management of young Fabrypatients"

Dr. Derralynn Hughes, Royal Free Hospital, UCL ,London (UK)  2How to diagnose and treat female Fabrypatients"

 

Inscripcions clicant en aquest enllaç

Més Informació:  Direcció de Comunicació, Màrqueting i RSC - Vall d’Hebron Barcelona Hospital Campus

comunica@vhir.org

 

 

Subscribe to our newsletters and be a part of Vall d'Hebron Campus

The acceptance of these terms implies that you give your consent to the processing of your personal data for the provision of the services you request through this portal and, if applicable, to carry out the necessary procedures with the administrations or public entities involved in the processing. You may exercise the mentioned rights by writing to web@vallhebron.cat, clearly indicating in the subject line “Exercise of LOPD rights”.
Responsible entity: Vall d’Hebron University Hospital (Catalan Institute of Health).
Purpose: Subscription to the Vall d’Hebron Barcelona Hospital Campus newsletter, where you will receive news, activities, and relevant information.
Legal basis: Consent of the data subject.
Data sharing: If applicable, with VHIR. No other data transfers are foreseen. No international transfer of personal data is foreseen.
Rights: Access, rectification, deletion, and data portability, as well as restriction and objection to its processing. The user may revoke their consent at any time.
Source: The data subject.
Additional information: Additional information can be found at https://hospital.vallhebron.com/es/politica-de-proteccion-de-datos.